Symmetry Surgical (SSRG) 10-Q 9 May 16 2016 Q1 Quarterly report Financial data

DOCUMENT AND ENTITY INFORMATION

DOCUMENT AND ENTITY INFORMATION - shares	3 Months Ended
	Apr. 02, 2016	May. 06, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	Symmetry Surgical Inc.
Entity Central Index Key	1,616,101
Current Fiscal Year End Date	--01-02
Entity Filer Category	Accelerated Filer
Trading Symbol	ssrg
Entity Common Stock, Shares Outstanding		10,740,184
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Apr. 2, 2016
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,016

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Apr. 02, 2016	Jan. 02, 2016
ASSETS:
Cash	$ 11,242	$ 8,072
Accounts receivable, net	9,045	10,922
Inventories	24,058	23,076
Other current assets	1,646	1,624
Total current assets	45,991	43,694
Property and equipment, net	2,117	2,258
Deferred income taxes	24,285	24,291
Goodwill	9,344	9,341
Intangible assets, net of accumulated amortization	72,377	73,719
Other assets	654	678
Total Assets	154,768	153,981
LIABILITIES AND EQUITY:
Accounts payable	6,680	6,240
Accrued wages and benefits	1,734	1,785
Other accrued expenses	1,136	1,540
Contingent purchase liability, current	2,073	1,047
Accrued income taxes	119	201
Total current liabilities	11,742	10,813
Contingent purchase liability, non-current	120	1,136
Other long-term liabilities	1,046	1,019
Total Liabilities	$ 12,908	$ 12,968
Commitments and contingencies
Stockholders' Equity:
Common Stock, $.0001 par value; 50,000 shares authorized; shares issued April 2, 2016-10,740; January 2, 2016-10,535	$ 1	$ 1
Additional paid-in capital	140,906	140,460
Retained earnings	1,358	1,084
Accumulated other comprehensive loss	(405)	(532)
Total Stockholders' Equity	141,860	141,013
Total Liabilities and Equity	$ 154,768	$ 153,981

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares shares in Thousands	Apr. 02, 2016	Jan. 02, 2016
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000	50,000
Common stock, shares issued	10,740	10,535

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Apr. 02, 2016	Apr. 04, 2015
Income Statement [Abstract]
Revenue	$ 21,240	$ 20,774
Cost of revenue	10,861	10,889
Gross profit	10,379	9,885
Sales and marketing expenses	4,699	4,473
General and administrative expenses	5,138	4,561
Operating income	542	851
Other (income) expense:
Interest expense	46	64
Other	188	(263)
Income before income taxes	308	1,050
Income tax expense	34	294
Net income	$ 274	$ 756
Net income per share:
Basic (in dollars per share)	$ 0.03	$ 0.08
Diluted (in dollars per share)	$ 0.03	$ 0.08
Weighted average common shares and equivalent shares outstanding:
Basic (in shares)	9,733	9,587
Diluted (in shares)	9,821	9,603

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2016	Apr. 04, 2015
Statement of Comprehensive Income [Abstract]
Net income	$ 274	$ 756
Other comprehensive income (loss):
Foreign currency translation adjustments	131	(307)
Pension plan actuarial gain (loss), net of taxes	(4)	29
Comprehensive income (loss)	$ 401	$ 478

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2016	Apr. 04, 2015
Operating activities
Net income	$ 274	$ 756
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	218	241
Amortization	1,359	1,400
Amortization of debt issuance costs	22	22
Net (gain) loss on sale of assets	0	2
Deferred income tax provision	12	121
Stock-based compensation	446	298
Unrealized foreign currency transaction (gain) loss	49	(26)
Change in operating assets and liabilities:
Accounts receivable	1,925	(167)
Other assets	8	183
Inventories	(982)	(1,022)
Current income taxes	(85)	156
Accounts payable	420	1,149
Accrued expenses and other	(521)	76
Net cash provided by operating activities	3,145	3,189
Investing activities
Purchases of property and equipment	(76)	(53)
Proceeds from sale of property and equipment	0	3
Net cash used in investing activities	(76)	(50)
Financing activities
Proceeds from Revolving Loan	0	69
Payments on Revolving Loan	0	(2,445)
Net cash provided by (used in) financing activities	0	(2,376)
Effect of exchange rate changes on cash	101	(337)
Net increase in cash	3,170	426
Cash at beginning of period	8,072
Cash at end of period	$ 11,242	$ 3,420

Description of Operations

Description of Operations	3 Months Ended
	Apr. 02, 2016
Nature of Operations [Abstract]
Description of Operations	Description of Operations Overview Symmetry Surgical Inc. (the “Company”) is a global marketer and distributor of medical devices with some limited manufacturing focused on the surgery market. The Company offers over 20,000 products and sells primarily to hospitals and surgical centers in the U.S. and countries worldwide. The Company's current product portfolio includes a broad range of reusable stainless steel and titanium, hand-held general and specialty surgical instruments, single use and disposable instruments, electro-surgery instruments, retractor systems, containers and sterilization devices, and ligation clips sold directly to hospitals and other sites of care. These products are typically used in the surgical specialties of neurosurgery, spine, general surgery- open and laparoscopy, microsurgery, OB/Gyn, ophthalmology, otolaryngology / ENT, plastic / reconstructive, peripheral vascular, arthroscopy, orthopedic, pediatrics, cardiovascular, thoracic, and urology in the hospital setting as well as surgery centers and in select physician offices. These products are viewed in two categories by management; Symmetry Surgical Branded Products and Alliance Partners Products. Symmetry Surgical Branded Products include all products sold under brand names managed by the Company whereas Alliance Partners Products are brands the Company distributes for others in defined markets. On August 28, 2015, the Company acquired the assets of Vesocclude Medical, LLC ("Vesocclude Medical" or "Vesocclude") for $4,055 in cash, gross of the Company's 4.8% existing minority interest in Vesocclude and up to an additional $2,200 in contingent consideration based on the achievement of milestones discussed in Note 4. Vesocclude's portfolio of titanium ligation clips and appliers are used in surgical procedures to close tubal anatomic structures such as blood vessels or ducts. Vesocclude products are primarily sold in the U.S. direct to hospitals but in some territories are sold through stocking distributors and kit packers. Internationally, Vesocclude products are sold through stocking distributors. On December 1, 2015, the Company acquired the patent protected, ultra-low profile, soft-tissue retraction technology and related product portfolio and other assets from privately held Insightra ® Medical for $400 in cash as well as a royalty on future sales with a fair value of $107 as of the date of acquisition. The portfolio, formerly known as ReeTrakt, will be re-launched under the Symmetry Surgical brand as the Symmetry Access™ Low Profile Retractor beginning in the first half of 2016. The Symmetry Access™ Low Profile Retractor is a single-use product with an ultra-low profile that supports minimal/small incision surgical procedures by providing better surgical access and field of view. Symmetry Surgical plans to launch this product through our existing sales channel in the U.S. and internationally. The Company includes the consolidated operations of Specialty Surgical Instrumentation, Inc. (d/b/a Symmetry Surgical Inc.), Olsen Medical, LLC, Symmetry Surgical Vesocclude, LLC, Symmetry Surgical Netherlands, CV, Symmetry Surgical Netherlands, BV, Symmetry Surgical, GmbH and Symmetry Surgical Switzerland, GmbH.

Basis of Presentation

Basis of Presentation	3 Months Ended
	Apr. 02, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements of the Company have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles ("GAAP") have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, the accompanying condensed consolidated financial statements contain all adjustments of a normal recurring nature considered necessary to present fairly the consolidated financial position of the Company, its results of operations and cash flows. The Company’s results are subject to seasonal fluctuations. Interim results are not necessarily indicative of results for a full year. The condensed consolidated financial statements included herein should be read in conjunction with the fiscal year 2015 consolidated and combined financial statements and the notes thereto included in the Company's Annual Report on Form 10-K for fiscal year 2015. The Company’s fiscal year is the 52 or 53 week period ending on the Saturday closest to December 31. Fiscal year 2016 is a 52 week year ending December 31, 2016. The Company’s interim quarters for 2016 are 13 weeks long and quarter-end dates have been set as April 2, 2016 , July 2, 2016 and October 1, 2016 . Fiscal year 2015 was a 52 week year (ending January 2, 2016 ). The Company’s interim quarters for 2015 were 13 weeks long, ending April 4, 2015 , July 4, 2015 and October 3, 2015 . References in these condensed consolidated financial statements to the three months ended refer to these financial periods, respectively.

Recently Adopted Accounting Pro

Recently Adopted Accounting Pronouncements	3 Months Ended
	Apr. 02, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements On April 5, 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. In other words, an “emerging growth company” may delay the adoption of certain accounting standards until those standards would otherwise apply to private companies and the Company has chosen to take advantage of this extended transition period. Revenue from Contracts with Customers: In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The ASU is effective for fiscal periods (including interim periods) beginning after December 15, 2017 and early adoption is not permitted for periods beginning before December 15, 2016. The ASU allows for either full retrospective or a modified retrospective transition method. The Company is currently assessing the potential impact of the adoption of ASU 2014-09 on its financial statements and related disclosures. Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. This new guidance states that a performance target that affects vesting of a share-based payment and that could be achieved after the requisite service period is a performance condition under ASC 718. This update is effective for annual and interim periods beginning after December 15, 2015. The Company does not believe this ASU will have an impact on its financial statements. Leases. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This new guidance will require lessees to reflect most leases on the balance sheet. The standard is effective for the Company beginning in fiscal 2020. Early adoption is permitted. The standard must be adopted using a modified retrospective transition, with the new guidance applied to the beginning of the earliest comparative period presented. The Company is evaluating the impact of the adoption of this guidance on its financial statements. Compensation - Stock Compensation: Improvements in Employee Share-Based Payment Accounting. In March 2016, the FASB issued ASU No. 2016-09, Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This new guidance outlines new provisions intended to simplify various aspects related to accounting for share-based payments and their presentation in the financial statements. The Company has elected to adopt this guidance in its financial statements as of January 3, 2016. The adoption of this standard, which requires the excess tax benefit resulting from the vesting of restricted stock to be recorded as an income tax benefit had an impact $86 for the three months ended April 2, 2016

Acquisitions

Acquisitions	3 Months Ended
	Apr. 02, 2016
Business Combinations [Abstract]
Acquisitions	Acquisitions On August 28, 2015, the Company acquired the assets of Vesocclude for $4,055 in cash and up to an additional $2,200 in contingent consideration; each of which are gross of the Company's 4.8% existing minority interest in Vesocclude. The contingent consideration involves two contingent purchase payments. Contingent purchase liability No. 1 is based on achieving certain milestones related to new product introduction. Contingent purchase liability No. 2 is based on reaching specified new product commercial sales levels. The settlement of these contingent purchase liabilities can be made in cash or the Company's common stock or any combination thereof at the Company's option. The Company believes the Vesocclude acquisition further expands its Symmetry Surgical branded product offerings and augments the geographic coverage of its sales force as well as allows Symmetry Surgical to extend its brand through the legacy Vesocclude sales channels both in the U.S. and internationally. The following table summarizes the fair value of the total consideration which has been preliminarily allocated to the fair value of the assets and liabilities acquired based on the Company's internal operational assessments and other analyses which are Level 3 measurements. The preliminary purchase price allocation has been completed based on all information currently available. Net cash consideration $ 3,860 Contingent purchase liability No. 1 1,034 Contingent purchase liability No. 2 1,013 Pre-existing ownership interest 186 Gain on pre-existing ownership interest 67 Fair value of total consideration $ 6,160 Inventory $ 962 Property and equipment 252 Acquired customers 1,010 Trademarks 280 Acquired technology and patents 800 Other assets, non-current 637 Non-compete 25 Net identifiable assets acquired $ 3,966 Goodwill $ 2,194 In accordance with accounting guidance, the Company estimated the fair value of the contingent consideration as of the acquisition date and included such contingent purchase liabilities as a component of total purchase price as noted above. The potential undiscounted amount of each future payment that the Company could be required to make under the agreement is between $0 and $2,200 in the aggregate. The fair value of the contingent consideration arrangement of $2,047 was estimated by applying a market approach. That measure is based on significant inputs that are not observable in the market, also referred to as Level 3 inputs. As of April 2, 2016, key assumptions include a discount rate of 13.16% and an estimated level of probability. Changes to the fair value of the contingent consideration, subsequent to the initial purchase date, have been reflected in the statement of operations, which totaled $26 of expense in fiscal 2015 and a $4 benefit during the three month period ended April 2, 2016. The purchase price of Vesocclude exceeded the fair value of identifiable tangible and intangible assets. Goodwill recorded is deductible for U.S. Federal income taxes. The purchase was accounted for as a business combination and the results of Vesocclude have been included in the Company's statements of operations since the date of acquisition. The pro forma impact of the acquisition on the Company's prior period statements of operations was not material. The acquisition includes a 20% minority interest in a medical device company and an option to purchase the remaining ownership interest. The Company will account for its 20% ownership interest as an equity method investment. On December 1, 2015, the Company acquired the patent protected, ultra-low profile, soft-tissue retraction technology and related product portfolio and other assets from privately held Insightra ® Medical for $400 in cash as well as a royalty on future sales. This royalty has been deemed a contingent purchase liability with a fair value of $107 as of the date of acquisition. The following table summarizes the fair value of the total consideration which has been preliminarily allocated to the fair value of the assets acquired and liabilities assumed based on the Company's internal operational assessments and other analyses which are Level 3 measurements. The preliminary purchase price allocation has been completed based on all information currently available. Cash consideration $ 400 Contingent purchase liability No. 3, non-current 107 Fair value of total consideration $ 507 Inventory $ 102 Property and equipment 30 Acquired technology and patents 341 Non-compete 5 Net identifiable assets acquired $ 478 Goodwill $ 29 In accordance with accounting guidance, the Company estimated the fair value of the contingent consideration as of the acquisition date and included such contingent purchase liabilities as a component of total purchase price as noted above. The potential undiscounted amount of each future payment that the Company could be required to make under the agreement is between $0 and $1,000 in the aggregate. The fair value of the contingent consideration arrangement of $107 was estimated by applying a market approach. That measure is based on significant inputs that are not observable in the market, also referred to as Level 3 inputs. As of April 2, 2016, key assumptions include a discount rate of 38.90% and an estimated level of probability. Changes to the fair value of the contingent consideration, subsequent to the initial purchase date, have been reflected in the statement of operations, which totaled $13 of expense during the three month period ended April 2, 2016. The purchase price of Insightra Medical exceeded the fair value of net identifiable tangible and intangible assets. Goodwill recorded is deductible for U.S. Federal income taxes. The purchase was accounted for as a business combination and the results of this acquisition did not have any significant impact to the 2015 consolidated statements of operations since its date of acquisition. The pro forma impact of the acquisition on the Company's prior period consolidated statements of operations was not material.

Inventories

Inventories	3 Months Ended
	Apr. 02, 2016
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consist of the following: April 2, January 2, (unaudited) Raw material $ 951 $ 1,032 Work-in-process 54 141 Finished goods 23,053 21,903 $ 24,058 $ 23,076

Property and Equipment

Property and Equipment	3 Months Ended
	Apr. 02, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment, including depreciable lives, consists of the following: April 2, January 2, (unaudited) Buildings and improvements (20 to 40 years) $ 572 $ 560 Machinery and equipment (5 to 15 years) 1,827 1,816 Office equipment (3 to 5 years) 3,730 3,686 Construction-in-progress 22 10 6,151 6,072 Less accumulated depreciation (4,034 ) (3,814 ) $ 2,117 $ 2,258

Intangible Assets

Intangible Assets	3 Months Ended
	Apr. 02, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets As of April 2, 2016, the balances of intangible assets, other than goodwill, were as follows: Weighted-Average Amortization Period Gross Intangible Assets Accumulated Amortization Net Intangible Assets (unaudited) (unaudited) (unaudited) (unaudited) Acquired customers 19 $ 92,380 $ (24,215 ) $ 68,165 Trademarks 13 4,014 (944 ) 3,070 Acquired technology, patents and other 13 1,521 (379 ) 1,142 Intangible assets subject to amortization 19 $ 97,915 $ (25,538 ) $ 72,377 As of January 2, 2016, the balances of intangible assets, other than goodwill, were as follows: Weighted-Average Amortization Period Gross Intangible Assets Accumulated Amortization Net Intangible Assets Acquired customers 19 $ 92,355 $ (22,961 ) $ 69,394 Trademarks 13 4,014 (866 ) 3,148 Acquired technology, patents and other 13 $ 1,521 $ (344 ) 1,177 Intangible assets subject to amortization 19 $ 97,890 $ (24,171 ) $ 73,719

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Apr. 02, 2016
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments Accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable, and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. As of April 2, 2016, the Company held contingent purchase liabilities required to be measured at fair value on a recurring basis. The Company's contingent purchase liabilities associated with the acquisitions of Vesocclude Medical and Insightra Medical are not observable. The fair value of these liabilities have unobservable inputs in which little or no market data exists, therefore requiring the Company to categorize these liabilities as Level 3 and to re-measure the liability using its own assumptions in accordance with ASC 820. The contingent liabilities will continue to be accounted for and measured at fair value until the contingencies are settled or expire. The fair value and carrying value of the Company's liabilities measured at fair value on a recurring basis is as follows: April 2, 2016 January 2, 2016 Fair Value Measurements Fair Value Measurements Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total (unaudited) Liabilities Contingent purchase liability #1 $ — $ — $ 1,047 $ 1,047 $ — $ — $ 1,047 $ 1,047 Contingent purchase liability #2 — — 1,026 1,026 — — 1,029 1,029 Contingent purchase liability #3 — — 120 120 — — 107 107 Total liabilities $ — $ — $ 2,193 $ 2,193 $ — $ — $ 2,183 $ 2,183 Certain nonfinancial assets and liabilities are measured at fair value on a nonrecurring basis and are subject to fair value adjustments in certain circumstances, such as when there is evidence of impairment. Assets and liabilities acquired in business combinations (see Note 4) are recorde d at their fair value as of the date of acquisition. The Company reviews for goodwill impairment annually on the first day of the fourth fiscal quarter and more frequently if circumstances indicate its carrying value may not be recoverable. When a quantitative assessment is deemed appropriate, the fair value of the reporting unit is determined using the income approach. The income approach focuses on the income-producing capability of an asset, measuring the current value of the asset by calculating the present value of its future economic benefits such as cash earnings, cost savings, tax structure and product offerings. Value indications are developed by discounting expected cash flows to their present value at a rate of return that incorporates the risk-free rate for the use of funds, the expected rate of inflation and risks associated with the reporting unit. These assets are classified within Level 3, in the event that the Company were required to measure and record such assets at fair value within its consolidated financial statements. The Company periodically evaluates the carrying value of long-lived assets to be held and used, including definite-lived intangible assets and property plant and equipment, when events or circumstances warrant such a review. Fair value is determined primarily using anticipated cash flows assumed by a market participant, discounted at a rate commensurate with the risk involved and these assets would generally be classified within Level 3, in the event that the Company were required to measure and record such assets at fair value within its consolidated financial statements. The interest rates on the Company's borrowings under the revolving credit facility are adjusted regularly to reflect current market rates and thus carrying value approximates fair value for these borrowings as there is no active market for our Revolving Loan which is classified as Level 3.

Debt Arrangements

Debt Arrangements	3 Months Ended
	Apr. 02, 2016
Debt Disclosure [Abstract]
Debt Arrangements	Debt Arrangements On December 5, 2014, the Company, Specialty Surgical Instrumentation, Inc. and Olsen Medical, LLC (collectively, the “Borrowers”) entered into a Credit Agreement (the “Credit Agreement”) with Capital One (formally known as General Electric Capital Corporation "GECC"), which provides for a revolving loan of up to $20,000 , subject to a borrowing base limitation (the "Revolving Loan"). The Credit Agreement, which is senior and secured, had $0 outstanding as of April 2, 2016 and January 2, 2016. Any amounts outstanding under the Revolving Loan are due and payable on December 5, 2019. Amounts outstanding under the Credit Agreement bear interest at LIBOR plus 3.25% , or the Base Rate (which will generally be based on the prime rate as published by the Wall Street Journal from time to time) plus 2.25% . Borrowings under the Revolving Loan are classified as current due to the existence of a cash dominion by Capital One. In August 2015, the Company amended the Credit Agreement to allow for the acquisition of Vesocclude Medical. The Company has deferred debt issuance costs of $324 and $346 as of April 2, 2016 and January 2, 2016, respectively, reflected in other current assets in the consolidated balance sheets. The Credit Agreement is guaranteed by Symmetry Surgical International, Inc., Symmetry Surgical Vesocclude LLC, S.S.I.I. LP, LLC and Symmetry Medical SSI Real Estate LLC (collectively the “Guarantors”). The Revolving Loan is secured by a first-priority perfected security interest in substantially all of the tangible and intangible assets of the Borrowers and the Guarantors, including a pledge of 100% of the equity interests of each domestic subsidiary. The Credit Agreement includes customary covenants for facilities of this type, including limitations on indebtedness, liens, investments and acquisitions, loans and advances, mergers and consolidations, sales of assets, and dividends, stock repurchases and other restricted payments. In addition, the Credit Agreement requires that Borrowers maintain a minimum fixed charge coverage ratio of 1.25 to 1.00 tested at the close of each fiscal quarter, based on the preceding four fiscal quarters, and maintain at all times minimum liquidity (the sum of cash, cash equivalent and available borrowing capacity under the borrowing base) of $1,500 , tested monthly. As of April 2, 2016, the borrowing base limitation was $12,415 and fully available. The Company was in compliance with all covenants as of April 2, 2016.

Income Taxes

Income Taxes	3 Months Ended
	Apr. 02, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For the three months ended April 2, 2016 and April 4, 2015, the Company recorded an income tax provision of $34 and $294 , respectively, representing an effective tax rate of 11% and 28% , respectively. For the three months ended April 2, 2016, the provision for income taxes differs from that computed at the Federal statutory rate of 34% in 2016 primarily due to the adoption of a new accounting pronouncement which requires the excess tax benefit resulting from the vesting of restricted stock to be recorded as an income tax benefit as well as state taxes. For the three months ended April 4, 2015, the provision for income taxes differs from that computed at the Federal statutory rate of 34% due to the impact of foreign operations. As of April 2, 2016, there were no uncertain tax positions.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Apr. 02, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Unconditional Purchase Obligations. The Company has a contract, which was effective September 2014, to purchase finished instruments through August 2019. Based on contractual pricing at April 2, 2016, the remaining minimum purchase obligation totaled $1,437 . Purchases under the contract totaled approximately $57 for the three months ended April 2, 2016. These purchases are not in excess of forecasted requirements. Legal & Environmental Matters. The Company is involved, from time to time, in various contractual, product liability, intellectual property and other claims and disputes incidental to its business. Currently, there is no environmental or other litigation pending or, to the knowledge of the Company, threatened, that the Company expects to have a material adverse effect on its financial condition, results of operations or liquidity. While litigation is subject to uncertainties and the outcome of litigated matters is not predictable with assurance, the Company currently believes that the disposition of all pending or, to the knowledge of the Company, threatened claims and disputes, individually or in the aggregate, should not have a material adverse effect on the Company’s consolidated financial position, results of operations or liquidity. Under the terms of the separation agreement between the Company and SMI, the Company agreed to indemnify SMI and its related entities from and against any and all liabilities relating to, arising out of or resulting from: any failure by the Company to pay, perform or otherwise promptly discharge any of the liabilities the Company agreed to assume with the Spin-Off; any of the Company's liabilities defined in the Merger Agreement; and any breach of any of the Merger Agreement, Separation Agreement or IP Cross-License Agreement. Liabilities that result from these obligations could result in significant, and in some cases uninsured, financial obligations. The Company does not believe this will have a significant impact on its financial position, results of operations or cash flows. In September 2013, Xodus Medical Inc., Alessio Pigazzi and Glenn Keilar (collectively “Xodus”) filed suit against Prime Medical, LLC (“Prime”), and Specialty Surgical Instrumentation, Inc. d/b/a Symmetry Surgical Inc. in the United States District Court for the Western District of Pennsylvania under cause number 2:13-cv-01372-AJS. In the lawsuit Xodus alleged that Prime, a manufacturer of products Symmetry Surgical distributes, had infringed on two of its patents, U.S. Patent No. 8,511,314 and US Patent No. 8,464,720 (the “Xodus Patents”) and that Symmetry Surgical was liable to it for damages resulting from selling products that infringed on the Xodus Patents. Symmetry Surgical’s Distribution Agreement with Prime provides Symmetry Surgical with full indemnification for these claims, and Prime has paid for all costs of litigation thus far. On February 24, 2014 the U.S. Patent and Trademarks Office ("USPTO") found substantial questions regarding the patentability of the Xodus Patents and on July 10, 2014 the USPTO rejected both of the Xodus Patents. Xodus has appealed to the full Board of the USPTO, a process that should be concluded in fiscal year 2016. Should the USPTO reverse its prior two findings, and should the US District Court find that Prime’s products infringe on the Xodus Patents, then Symmetry Surgical may be found liable to Xodus for some percentage of its sales of the Prime products, to the extent that Prime is unable to satisfy its indemnity obligations. On September 29, 2014, a purported class action complaint challenging the company’s former parent’s merger and the Company’s spin-out as a stand-alone public company was filed by Resolution Partners, an alleged stockholder of SMI, and all others similarly situated, in the Kosciusko Circuit Court in the state of Indiana. The complaint named as defendants Symmetry Medical Inc. (“SMI”), the members of the board of directors of SMI, Genstar Capital LLC, Tecomet’s sponsor (‘‘Genstar’’), Tecomet, Holdings and TecoSym Inc. The complaint generally alleges, among other things, that the members of the SMI board of directors breached their fiduciary duties to Resolution Partners and SMI stockholders during merger negotiations and by entering into the Merger Agreement and approving the Merger, and that Genstar and Tecomet allegedly aided and abetted such alleged breaches of fiduciary duties. The complaint further alleges that the joint proxy statement/prospectus filed by Symmetry Surgical with the SEC on September 5, 2014, which contained the preliminary proxy statement of SMI, was misleading or omitted certain allegedly material information. The complaint sought, among other relief, injunctive relief enjoining consummation of the Merger, compensatory and/or rescissory damages in an unspecified amount and costs and fees. The parties settled the suit prior to the consummation of the transaction, for no additional consideration and a few additional disclosures filed in a Form 8-k, although left the issue of a claim for fees and costs for resolution at a later time, either through agreement or via a court hearing. The Company has agreed with SMI to share equally in any fee award, up to 50% of the remaining insurance deductible. The parties have agreed to a settlement of all claims based on the Form 8-k that was filed prior to the closing on the transaction and which shared additional information related to it. There is a settlement conference scheduled for May 13, 2016 to confirm settlement. The Company does not believe this will have a significant impact on its financial position, results of operations or cash flows.

Net Income Per Share

Net Income Per Share	3 Months Ended
	Apr. 02, 2016
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Net Income Per Share The following table sets forth the computation of earnings per share. Three Months Ended April 2, 2016 April 4, 2015 (unaudited) Net income for basic earnings per share: Income available to common shares - Basic $ 274 $ 756 Basic weighted average common shares outstanding 9,733 9,587 Net income attributable to common shareholders $ 0.03 $ 0.08 Net income for diluted earnings per share: Income available to common shares - Diluted $ 274 $ 756 Basic weighted average common shares outstanding 9,733 9,587 Effect of dilution 88 16 Diluted weighted average common shares outstanding 9,821 9,603 Net income attributable to common shareholders $ 0.03 $ 0.08 As of April 2, 2016, the diluted weighted average share calculation does not include performance based restricted stock awarded in 2014 and 2015 totaling 735 shares due to the performance criteria not being completed.

Product and Geographic Informat

Product and Geographic Information	3 Months Ended
	Apr. 02, 2016
Segment Reporting [Abstract]
Product and Geographic Information	Product and Geographic Information The Company has one operating segment which is the lowest level for which discrete financial information is available and the operating results are regularly reviewed by management. The Company sells a broad range of reusable stainless steel and titanium hand-held instruments and retractor systems, ligation clips, single use and sterile disposable surgical products (vein strippers, SECTO dissectors, tonsil sponges and surgical marker pens), and sterilization containers. These products are typically used in the surgical specialties of spine, general/OB-GYN, microsurgery/neurosurgery, orthopedics, laparoscopy, cardiovascular, thoracic, and general surgery in the hospital setting as well as surgery centers and in select physician offices. These products are viewed in two categories by management; Symmetry Surgical Branded Products and Alliance Partners Products. Symmetry Surgical Branded Products include all products sold under brand names managed by the Company whereas Alliance Partners Products are brands the Company distributes for others in defined markets. Prior to the acquisition of the assets of Vesocclude Medical in August 2015, the revenue from the sales of Vesocclude product were depicted in the Alliance Partners product category. Upon acquisition, this revenue is now Symmetry Surgical branded product. For the purposes of comparability between periods, the historical product categories have been reclassified to include Vesocclude revenue in Symmetry Surgical branded product category. Revenues are attributed to geographic locations based on the location to which the Company ships its products. Revenues to External Customers: Three Months Ended Revenue by Geography April 2, 2016 April 4, 2015 (unaudited) United States $ 18,815 $ 17,854 International 2,425 2,920 Total revenues $ 21,240 $ 20,774 Revenues by Product: Three Months Ended April 2, 2016 April 4, 2015 (unaudited) Symmetry Surgical branded $ 19,374 $ 19,034 Alliance Partners 1,866 1,740 Total revenues $ 21,240 $ 20,774

Subsequent Events

Subsequent Events	3 Months Ended
	Apr. 02, 2016
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On May 2, 2016, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Symmetry Surgical Holdings, Inc., a Delaware corporation (“Parent”), and Symmetry Acquisition Corp, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”), pursuant to which Merger Sub will merge with and into the Company, with the Company surviving as a wholly-owned subsidiary of Parent (the “Merger”). Parent and Merger Sub are beneficially owned by an affiliate of RoundTable Healthcare Partners. The Merger Agreement was unanimously approved by the Company’s Board of Directors on May 2, 2016. At the effective time of the Merger, each share of Company common stock issued and outstanding immediately prior to the effective time of the Merger (other than shares owned by (i) the Company, Parent, Merger Sub or any direct or indirect subsidiary of any of the Company, Parent or Merger Sub immediately prior to the effective time of the Merger or (ii) stockholders who have properly exercised and perfected appraisal rights under Delaware law) will be converted automatically into the right to receive $13.10 in cash, without interest (the “Merger Consideration”). Company stock-based awards, including restricted stock, will generally be cancelled and converted automatically into a right to receive the Merger Consideration upon completion of the Merger. All performance-based vesting criteria in respect of stock-based awards will generally be deemed earned at the target level of performance for purposes of calculating amounts payable. Each party’s obligation to implement the Merger is subject to certain customary conditions, including, without limitation: (i) the affirmative vote of the holders of a majority of outstanding shares of the Company’s common stock to adopt the Merger Agreement, (ii) the expiration or early termination of all applicable waiting periods (and any extensions thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and applicable antitrust and competition laws of other jurisdictions in connection with the Merger and receipt of any required approvals thereunder, (iii) the absence of any order issued or pending seeking to enjoin the Merger or any of the other transactions contemplated by the Merger Agreement, (iv) the truth and accuracy of the parties’ respective representations and warranties in the Merger Agreement (generally subject to certain materiality and other qualifiers, as set forth in the Merger Agreement), and (v) the performance of, and compliance with, the parties’ respective agreements and covenants under the Merger Agreement in all material respects. The Merger Agreement provides that the Company must pay Parent a termination fee of $5,600 if the Merger Agreement is terminated under certain circumstances as described in the Merger Agreement. The Company is obligated to pay the reasonable and documented out-of-pocket fees and expenses of Parent and Merger Sub up to a cap of $2,750

Recently Adopted Accounting P21

Recently Adopted Accounting Pronouncements Recently Adopted Accounting Pronouncements (Policies)	3 Months Ended
	Apr. 02, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recently Adopted Accounting Pronouncements	On April 5, 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. In other words, an “emerging growth company” may delay the adoption of certain accounting standards until those standards would otherwise apply to private companies and the Company has chosen to take advantage of this extended transition period. Revenue from Contracts with Customers: In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) 605, Revenue Recognition. This ASU is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The ASU also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The ASU is effective for fiscal periods (including interim periods) beginning after December 15, 2017 and early adoption is not permitted for periods beginning before December 15, 2016. The ASU allows for either full retrospective or a modified retrospective transition method. The Company is currently assessing the potential impact of the adoption of ASU 2014-09 on its financial statements and related disclosures. Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. In June 2014, the FASB issued ASU 2014-12, Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. This new guidance states that a performance target that affects vesting of a share-based payment and that could be achieved after the requisite service period is a performance condition under ASC 718. This update is effective for annual and interim periods beginning after December 15, 2015. The Company does not believe this ASU will have an impact on its financial statements. Leases. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). This new guidance will require lessees to reflect most leases on the balance sheet. The standard is effective for the Company beginning in fiscal 2020. Early adoption is permitted. The standard must be adopted using a modified retrospective transition, with the new guidance applied to the beginning of the earliest comparative period presented. The Company is evaluating the impact of the adoption of this guidance on its financial statements. Compensation - Stock Compensation: Improvements in Employee Share-Based Payment Accounting. In March 2016, the FASB issued ASU No. 2016-09, Compensation — Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This new guidance outlines new provisions intended to simplify various aspects related to accounting for share-based payments and their presentation in the financial statements. The Company has elected to adopt this guidance in its financial statements as of January 3, 2016. The adoption of this standard, which requires the excess tax benefit resulting from the vesting of restricted stock to be recorded as an income tax benefit had an impact $86 for the three months ended April 2, 2016

Acquisitions (Tables)

Acquisitions (Tables)	3 Months Ended
	Apr. 02, 2016
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the fair value of the total consideration which has been preliminarily allocated to the fair value of the assets and liabilities acquired based on the Company's internal operational assessments and other analyses which are Level 3 measurements. The preliminary purchase price allocation has been completed based on all information currently available. Net cash consideration $ 3,860 Contingent purchase liability No. 1 1,034 Contingent purchase liability No. 2 1,013 Pre-existing ownership interest 186 Gain on pre-existing ownership interest 67 Fair value of total consideration $ 6,160 Inventory $ 962 Property and equipment 252 Acquired customers 1,010 Trademarks 280 Acquired technology and patents 800 Other assets, non-current 637 Non-compete 25 Net identifiable assets acquired $ 3,966 Goodwill $ 2,194 The following table summarizes the fair value of the total consideration which has been preliminarily allocated to the fair value of the assets acquired and liabilities assumed based on the Company's internal operational assessments and other analyses which are Level 3 measurements. The preliminary purchase price allocation has been completed based on all information currently available. Cash consideration $ 400 Contingent purchase liability No. 3, non-current 107 Fair value of total consideration $ 507 Inventory $ 102 Property and equipment 30 Acquired technology and patents 341 Non-compete 5 Net identifiable assets acquired $ 478 Goodwill $ 29

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Apr. 02, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories consist of the following: April 2, January 2, (unaudited) Raw material $ 951 $ 1,032 Work-in-process 54 141 Finished goods 23,053 21,903 $ 24,058 $ 23,076

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Apr. 02, 2016
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, including depreciable lives, consists of the following: April 2, January 2, (unaudited) Buildings and improvements (20 to 40 years) $ 572 $ 560 Machinery and equipment (5 to 15 years) 1,827 1,816 Office equipment (3 to 5 years) 3,730 3,686 Construction-in-progress 22 10 6,151 6,072 Less accumulated depreciation (4,034 ) (3,814 ) $ 2,117 $ 2,258

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Apr. 02, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	As of April 2, 2016, the balances of intangible assets, other than goodwill, were as follows: Weighted-Average Amortization Period Gross Intangible Assets Accumulated Amortization Net Intangible Assets (unaudited) (unaudited) (unaudited) (unaudited) Acquired customers 19 $ 92,380 $ (24,215 ) $ 68,165 Trademarks 13 4,014 (944 ) 3,070 Acquired technology, patents and other 13 1,521 (379 ) 1,142 Intangible assets subject to amortization 19 $ 97,915 $ (25,538 ) $ 72,377 As of January 2, 2016, the balances of intangible assets, other than goodwill, were as follows: Weighted-Average Amortization Period Gross Intangible Assets Accumulated Amortization Net Intangible Assets Acquired customers 19 $ 92,355 $ (22,961 ) $ 69,394 Trademarks 13 4,014 (866 ) 3,148 Acquired technology, patents and other 13 $ 1,521 $ (344 ) 1,177 Intangible assets subject to amortization 19 $ 97,890 $ (24,171 ) $ 73,719

Fair Value of Financial Instr26

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Apr. 02, 2016
Fair Value Disclosures [Abstract]
Schedule of Liabilities Measured on Recurring Basis	The fair value and carrying value of the Company's liabilities measured at fair value on a recurring basis is as follows: April 2, 2016 January 2, 2016 Fair Value Measurements Fair Value Measurements Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total (unaudited) Liabilities Contingent purchase liability #1 $ — $ — $ 1,047 $ 1,047 $ — $ — $ 1,047 $ 1,047 Contingent purchase liability #2 — — 1,026 1,026 — — 1,029 1,029 Contingent purchase liability #3 — — 120 120 — — 107 107 Total liabilities $ — $ — $ 2,193 $ 2,193 $ — $ — $ 2,183 $ 2,183

Net Income Per Share (Tables)

Net Income Per Share (Tables)	3 Months Ended
	Apr. 02, 2016
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table sets forth the computation of earnings per share. Three Months Ended April 2, 2016 April 4, 2015 (unaudited) Net income for basic earnings per share: Income available to common shares - Basic $ 274 $ 756 Basic weighted average common shares outstanding 9,733 9,587 Net income attributable to common shareholders $ 0.03 $ 0.08 Net income for diluted earnings per share: Income available to common shares - Diluted $ 274 $ 756 Basic weighted average common shares outstanding 9,733 9,587 Effect of dilution 88 16 Diluted weighted average common shares outstanding 9,821 9,603 Net income attributable to common shareholders $ 0.03 $ 0.08

Product and Geographic Inform28

Product and Geographic Information (Tables)	3 Months Ended
	Apr. 02, 2016
Segment Reporting [Abstract]
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area	Revenues to External Customers: Three Months Ended Revenue by Geography April 2, 2016 April 4, 2015 (unaudited) United States $ 18,815 $ 17,854 International 2,425 2,920 Total revenues $ 21,240 $ 20,774
Schedule of Product Information	Revenues by Product: Three Months Ended April 2, 2016 April 4, 2015 (unaudited) Symmetry Surgical branded $ 19,374 $ 19,034 Alliance Partners 1,866 1,740 Total revenues $ 21,240 $ 20,774

Description of Operations (Deta

Description of Operations (Details) - Vesocclude Medical, LLC (Vesocclude) [Member] $ in Thousands	Aug. 28, 2015USD ($)
Business Combination, Separately Recognized Transactions [Line Items]
Cash consideration	$ 4,055
Minority interest	4.80%
Potential payments based on achievements	$ 2,047
Maximum [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Potential payments based on achievements	$ 2,200

Basis of Presentation (Details)

Basis of Presentation (Details)	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Oct. 01, 2016	Jul. 02, 2016	Apr. 02, 2016	Jan. 02, 2016	Oct. 03, 2015	Jul. 04, 2015	Apr. 04, 2015	Dec. 31, 2016	Jan. 02, 2016
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Number of weeks in fiscal year										364 days
Number of weeks in interim quarter				91 days	91 days	91 days	91 days	91 days
Minimum [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Number of weeks in fiscal year				364 days
Maximum [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Number of weeks in fiscal year				371 days
Scenario, Forecast [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Number of weeks in fiscal year									364 days
Number of weeks in interim quarter	91 days	91 days	91 days

Recently Adopted Accounting P31

Recently Adopted Accounting Pronouncements (Details) $ in Thousands	3 Months Ended
	Apr. 02, 2016USD ($)
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Share-based compensation, excess tax benefit, amount	$ (86)

Acquisitions (Narrative) (Detai

Acquisitions (Narrative) (Details) - USD ($) $ in Thousands	Dec. 01, 2015	Aug. 28, 2015	Apr. 02, 2016	Jan. 02, 2016
Vesocclude Medical, LLC (Vesocclude) [Member]
Business Acquisition [Line Items]
Cash consideration		$ 4,055
Potential payments based on achievements		$ 2,047
Minority interest		4.80%
Discount rate		13.16%
Liabilities arising from contingencies, amount recognized				$ 26
Assets arising from contingencies, amount recognized			$ 4
Vesocclude Medical, LLC (Vesocclude) [Member] | Medical Device [Member]
Business Acquisition [Line Items]
Minority interest		20.00%
Vesocclude Medical, LLC (Vesocclude) [Member] | Maximum [Member]
Business Acquisition [Line Items]
Potential payments based on achievements		$ 2,200
Potential undiscounted amount of each future payment		2,200
Vesocclude Medical, LLC (Vesocclude) [Member] | Minimum [Member]
Business Acquisition [Line Items]
Potential undiscounted amount of each future payment		$ 0
Insightra® Medical [Member]
Business Acquisition [Line Items]
Cash consideration	$ 400
Potential payments based on achievements	107
Discount rate		38.90%
Liabilities arising from contingencies, amount recognized			$ 13
Royalty on future sales, fair value	$ 107
Insightra® Medical [Member] | Maximum [Member]
Business Acquisition [Line Items]
Potential undiscounted amount of each future payment		$ 1,000
Insightra® Medical [Member] | Minimum [Member]
Business Acquisition [Line Items]
Potential undiscounted amount of each future payment		$ 0

Acquisitions (Schedule of Asset

Acquisitions (Schedule of Assets and Liabilities Assumed) (Details) - USD ($) $ in Thousands	Dec. 01, 2015	Aug. 28, 2015	Apr. 02, 2016	Jan. 02, 2016
Business Acquisition [Line Items]
Goodwill			$ 9,344	$ 9,341
Insightra® Medical [Member]
Business Acquisition [Line Items]
Cash consideration	$ 400
Insightra® Medical [Member] | Level 3 [Member]
Business Acquisition [Line Items]
Cash consideration	400
Contingent purchase liability No. 3, non-current	107
Fair value of total consideration	507
Inventory	102
Property and equipment	30
Finite-lived intangibles	478
Goodwill	29
Insightra® Medical [Member] | Level 3 [Member] | Acquired Technology and Patents [Member]
Business Acquisition [Line Items]
Finite-lived intangibles	341
Insightra® Medical [Member] | Level 3 [Member] | Noncompete Agreements [Member]
Business Acquisition [Line Items]
Finite-lived intangibles	$ 5
Vesocclude Medical, LLC (Vesocclude) [Member]
Business Acquisition [Line Items]
Cash consideration		$ 4,055
Vesocclude Medical, LLC (Vesocclude) [Member] | Level 3 [Member]
Business Acquisition [Line Items]
Net cash consideration		3,860
Contingent purchase liability No. 1		1,034
Contingent purchase liability No. 2		1,013
Pre-existing ownership interest		186
Gain on pre-existing ownership interest		67
Fair value of total consideration		6,160
Inventory		962
Property and equipment		252
Other assets, non-current		637
Net identifiable assets acquired		3,966
Goodwill		2,194
Vesocclude Medical, LLC (Vesocclude) [Member] | Level 3 [Member] | Acquired Customers [Member]
Business Acquisition [Line Items]
Finite-lived intangibles		1,010
Vesocclude Medical, LLC (Vesocclude) [Member] | Level 3 [Member] | Trademarks [Member]
Business Acquisition [Line Items]
Finite-lived intangibles		280
Vesocclude Medical, LLC (Vesocclude) [Member] | Level 3 [Member] | Acquired Technology and Patents [Member]
Business Acquisition [Line Items]
Finite-lived intangibles		800
Vesocclude Medical, LLC (Vesocclude) [Member] | Level 3 [Member] | Noncompete Agreements [Member]
Business Acquisition [Line Items]
Finite-lived intangibles		$ 25

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Apr. 02, 2016	Jan. 02, 2016
Inventory Disclosure [Abstract]
Raw material	$ 951	$ 1,032
Work-in-process	54	141
Finished goods	23,053	21,903
Inventories, net	$ 24,058	$ 23,076

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2016	Jan. 02, 2016
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 6,151	$ 6,072
Less accumulated depreciation	(4,034)	(3,814)
Property and equipment, net	2,117	2,258
Buildings and Improvement [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 572	560
Buildings and Improvement [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	20 years
Buildings and Improvement [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	40 years
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,827	1,816
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	5 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	15 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 3,730	3,686
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	3 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	5 years
Construction-in-Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 22	$ 10

Intangible Assets (Balances of

Intangible Assets (Balances of Intangible Assets, Other than Goodwill) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Apr. 02, 2016	Jan. 02, 2016
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Period	19 years	19 years
Gross Intangible Assets	$ 97,915	$ 97,890
Accumulated Amortization	(25,538)	(24,171)
Net Intangible Assets	$ 72,377	$ 73,719
Acquired Customers [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Period	19 years	19 years
Gross Intangible Assets	$ 92,380	$ 92,355
Accumulated Amortization	(24,215)	(22,961)
Net Intangible Assets	$ 68,165	$ 69,394
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Period	13 years	13 years
Gross Intangible Assets	$ 4,014	$ 4,014
Accumulated Amortization	(944)	(866)
Net Intangible Assets	$ 3,070	$ 3,148
Acquired Technology Patents and Other [Member]
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Period	13 years	13 years
Gross Intangible Assets	$ 1,521	$ 1,521
Accumulated Amortization	(379)	(344)
Net Intangible Assets	$ 1,142	$ 1,177

Fair Value of Financial Instr37

Fair Value of Financial Instruments (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Apr. 02, 2016	Jan. 02, 2016
Liabilities
Contingent purchase liability 1	$ 1,047	$ 1,047
Contingent purchase liability 2	1,026	1,029
Contingent purchase liability 3	120	107
Total liabilities	2,193	2,183
Fair Value, Inputs, Level 1 [Member]
Liabilities
Contingent purchase liability 1	0	0
Contingent purchase liability 2	0	0
Contingent purchase liability 3	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Liabilities
Contingent purchase liability 1	0	0
Contingent purchase liability 2	0	0
Contingent purchase liability 3	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Liabilities
Contingent purchase liability 1	1,047	1,047
Contingent purchase liability 2	1,026	1,029
Contingent purchase liability 3	120	107
Total liabilities	$ 2,193	$ 2,183

Debt Arrangements (Details)

Debt Arrangements (Details) - Revolving Credit Facility [Member] - Secured Debt [Member]	3 Months Ended
	Apr. 02, 2016USD ($)	Apr. 04, 2015USD ($)	Dec. 05, 2014USD ($)
Schedule of Long-term and Short-term Debt [Line Items]
Maximum borrowing capacity			$ 20,000,000
Revolving line of credit	$ 0
Deferred debt issuance costs	$ 324,000	$ 346,000
Fixed charge coverage ratio	1.25
Liquidity requirement	$ 1,500,000
Borrowing limitation, available amount	$ 12,415,000
LIBOR [Member]
Schedule of Long-term and Short-term Debt [Line Items]
Basis spread on variable rate	3.25%
Base Rate [Member]
Schedule of Long-term and Short-term Debt [Line Items]
Basis spread on variable rate	2.25%

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2016	Apr. 04, 2015
Income Tax Disclosure [Abstract]
Income tax expense	$ 34	$ 294
Effective tax rate, percent	11.00%	28.00%
Federal statutory income tax rate, percent	34.00%	34.00%

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2016	Sep. 29, 2014
Commitments and Contingencies Disclosure [Abstract]
Unconditional purchase obligations contract price	$ 1,437
Unrecorded unconditional purchase obligation, purchases	$ 57
Remaining insurance deductibles, maximum percent of sharing		50.00%

Net Income Per Share (Details)

Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Apr. 02, 2016	Apr. 04, 2015
Net income for basic earnings per share:
Income available to common shares - Basic	$ 274	$ 756
Basic weighted average common shares outstanding	9,733	9,587
Net income attributable to common shareholders	$ 0.03	$ 0.08
Net income for diluted earnings per share:
Income available to common shares - Diluted	$ 274	$ 756
Basic weighted average common shares outstanding	9,733	9,587
Effect of dilution	88	16
Diluted weighted average common shares outstanding	9,821	9,603
Net income attributable to common shareholders	$ 0.03	$ 0.08
Performance-based shares excluded in the calculation of diluted EPS	735

Product and Geographic Inform42

Product and Geographic Information (Details Textual)	3 Months Ended
	Apr. 02, 2016segment
Segment Reporting [Abstract]
Number of operating segments	1

Product and Geographic Inform43

Product and Geographic Information (Details 1) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2016	Apr. 04, 2015
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 21,240	$ 20,774
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	18,815	17,854
International [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 2,425	$ 2,920

Product and Geographic Inform44

Product and Geographic Information (Details 2) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2016	Apr. 04, 2015
Segment Reporting Information [Line Items]
Revenue	$ 21,240	$ 20,774
Symmetry Surgical [Member]
Segment Reporting Information [Line Items]
Revenue	19,374	19,034
Alliance Partners [Member]
Segment Reporting Information [Line Items]
Revenue	$ 1,866	$ 1,740

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member] - RoundTable Healthcare Partners (RoundTable) [Member] $ / shares in Units, $ in Thousands	May. 02, 2016USD ($)$ / shares
Subsequent Event [Line Items]
Common stock, sale rice per share | $ / shares	$ 13.10
Sell of common stock, termination fee	$ 5,600
Maximum [Member]
Subsequent Event [Line Items]
Sell of common stock, reimbursement amount of sale expenses	$ 2,750